19 August | August 2026 CTAC meeting summary of provisional recommendations added
17 July 2026 | June 2026 CTAC meeting summary of provisional recommendations added
Members of the Cancer Treatments Advisory Committee
Prof Stephen Munn – Transplant Surgeon (Chair, PTAC Member)
Dr Matthew Strother – Medical Oncologist (PTAC Member)
Dr Scott Babington – Radiation Oncologist
Dr Oliver Brake – Haematologist
Prof Christopher Frampton – Biostatistician
Dr Richard Isaacs – Medical Oncologist
Dr Allanah Kilfoyle – Haematologist
Dr Michael Lau – Anatomical Pathologist
Dr Vidya Mathavan – Haematologist
Dr Alice Minhinnick – Medical Oncologist
Dr Lochie Teague – Paediatric Haematologist / Oncologist
Dr Michelle Wilson – Medical Oncologist
2026 Committee meetings
Due to a high volume of funding applications, we have scheduled a series of meetings across 2026 for the Cancer Treatments Advisory Committee. These meetings will include both full-day and half-day sessions.
Agendas and provisional recommendations will be added as they are finalised.
Mirvetuximab soravtansine-gynx(external link)for treatment of folate receptor alpha high, platinum resistant, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, within the context of treatments for malignancy, subject to Special Authority criteria
Medium priority
Pembrolizumab(external link)for first-line treatment of advanced or recurrent dMMR endometrial cancer, in combination with chemotherapy, followed by maintenance monotherapy, within the context of treatments for malignancy, subject to Special Authority criteria
High priority
Pembrolizumab(external link)for first-line treatment of advanced or recurrent pMMR endometrial cancer, in combination with chemotherapy, followed by maintenance monotherapy, within the context of treatments for malignancy, subject to Special Authority criteria
Medium priority
Pembrolizumab(external link)for second-line treatment of advanced or recurrent dMMR endometrial cancer, as monotherapy, within the context of treatments for malignancy, subject to Special Authority criteria
High priority
Pembrolizumab(external link)for second-line treatment of advanced or recurrent pMMR endometrial cancer, in combination with lenvatinib, within the context of treatments for malignancy, subject to Special Authority criteria
High priority
Durvalumab(external link)for first-line treatment of advanced, metastatic or recurrent dMMR endometrial cancer, in combination with chemotherapy, followed by maintenance monotherapy, within the context of treatments for malignancy, subject to Special Authority criteria
High priority
Durvalumab(external link)for first-line treatment of advanced, metastatic or recurrent, pMMR endometrial cancer, in combination with chemotherapy, followed by maintenance durvalumab in combination with olaparib, within the context of treatments for malignancy, subject to Special Authority criteria
Medium priority
Durvalumab(external link)for first-line treatment of advanced, metastatic or recurrent, endometrial cancer (all comers), in combination with chemotherapy, followed by maintenance durvalumab as monotherapy or in combination with olaparib, within the context of treatments for malignancy, subject to Special Authority criteria
Trabectedin(external link)for the treatment of first line treatment of leiomyosarcoma, unresectable or metastatic, within the context of treatments for malignancy, subject to Special Authority criteria
High priority
Trabectedin(external link)for the treatment of second line treatment of liposarcoma or leiomyosarcoma, unresectable or metastatic, within the context of treatments for malignancy, subject to Special Authority criteria
Low priority
Eribulin(external link)for the treatment of advanced liposarcoma (following chemotherapy), within the context of treatments for malignancy, subject to Special Authority criteria
*Withheld
Ruxolitinib(external link)for the treatment of polycythaemia vera, intolerant or resistant to hydroxycarbamide (hydroxyurea), within the context of treatments for malignancy, subject to Special Authority criteria
Medium priority
*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until full record is available.
Alectinib(external link)for the treatment of resected, anaplastic lymphoma kinase-positive (ALK-positive) non-small cell lung cancer, within the context treatments for malignancy, subject to Special Authority criteria
Medium priority
Durvalumab(external link)for the treatment of limited-stage, small cell lung cancer, within the context treatments for malignancy, subject to Special Authority criteria
High priority
Inavolisib(external link)for the treatment of HR-positive, HER2-negative, locally advanced or metastatic breast cancer, with aPIK3CAmutation, within the context treatments for malignancy, subject to Special Authority criteria
Medium priority
Ibrutinib(external link)for the treatment of mantle cell lymphoma, as an alternative to autologous stem cell transplant, within the context treatments for malignancy, subject to Special Authority criteria
High priority
Blinatumomab(external link)for the treatment of B-cell lineage acute lymphoblastic leukaemia (ALL), with no measurable residual disease (MRD-negative), within the context treatments for malignancy, subject to Special Authority criteria
Pertuzumab and trastuzumab(external link)for the adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence, within the context for treatments for malignancy, subject to Special Authority criteria
*Withheld
Pertuzumab and trastuzumab(external link)widened access for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer with an ECOG status score 2-3, within the context for treatments for malignancy, subject to Special Authority criteria
Medium priority
Belzutifan(external link)for the treatment of tumours associated with Von-Hippel Lindau disease, within the context for treatments for malignancy, subject to Special Authority criteria
Medium priority
Eltrombopag(external link)widened access for the first line treatment of severe aplastic anaemia in combination with immunosuppressive therapy, within the context for treatments for haematology, subject to Special Authority criteria
High priority
Eltrombopag(external link)widened access for the second-line treatment of relapsed/refractory severe aplastic anaemia in combination with immunosuppressive therapy, within the context for treatments for haematology, subject to Special Authority criteria
High Priority
*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until the full record is available.
